AstraZeneca Pharma India Ltd. — Earnings Release 2019

Aug 9, 2019

==> picture [27 x 41] intentionally omitted <==

AstraZeneca

==> picture [87 x 72] intentionally omitted <==

----- Start of picture text -----

4
1 , .. �)
A ✓
O,lnglng 1denu lo p1tltnts sine• 1979 t:,
----- End of picture text -----

August 9, 20 I 9

The Manger - Listing BSE Limited Corporate Relationship Dept., I[st ] Floor, New Trading Ring Rotunda Building, P J Towers, Dalal Street, Fort, Mumbai 40000 I

National Stock Exchange of India Ltd. Exchange plaza, 5[th ] Floor, Plot No.C/l, G Block Bandra-Kurla Complex, Bandra (E), Mumbai 400051

Dear Sir(s),

Sub: Newspaper advertisement regarding 01 2019-20 financial results

- Ref: Scrip Code BSE: 506820, NSE: ASTRAZEN

Pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose adve1tisernents given in Business Standard and Udayavani on August 9, 2019 in respect of the Unaudited Financial Results for quarter ended June 30, 2019 approved in the Board Meeting of the Company held on August 7, 2019.

This is for your information and records.

For AstraZeneca Pharma India limited

==> picture [74 x 74] intentionally omitted <==

==> picture [114 x 39] intentionally omitted <==

Pratap Rudra Company Secretary & Legal Counsel

TEL : +91 80 6774 8000 FAX : +91 80 6774 8857 CIN : L24231KA1979PLC003563

TEL : +91 80 6774 9000

CORPORATE & REGO. OFFICE AstraZeneca Pharma India Ltd. P. B. No. 4525, Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore - 560 045, INDIA

FACTORY TEL : +91 80 6774 9000 12th Mile on Bellary Road Venkatala, Kattigenahalli Village FAX : +91 80 2846 2208 Yelahanka Bangalore - 560 063 +91 80 6774 9628 INDIA

WEB : www.astrazeneca.com/india

BENGALURU

==> picture [30 x 12] intentionally omitted <==

FRIDAY, 9 AuGusr 2019 Business Standard

AstraZeneca 4> AstraZeneca Pharma India Limited

CIN: L24231KA1979PLC003563

Regd. Office: Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore - 560 045. Tel.: +91 80 6774 8000. Web: www.astrazeneca.com/india

Statement of unaudited financial results for the quarter ended 30 June 2019

		Rs. Inlakhs except for earings par share data	Rs. Inlakhs except for earings par share data
SI. No.	Pariculars	3 months Corresponding ended 3 monthsendedInthe 30/06/2019 previousyear 30/06/2018	Year ended 31/03/2019
		Unaudited Unaudited	Audited
1 2 3 4 5 6 7	Total income from operations Net profit/ {loss) for the period from ordinar act1v1ties before tax Net profit/ {loss) for the period from ordinar act1v1ties afer tax Total comprehensive income for the perod afer tax Equity Share Capital Reseres {excluding revaluation reseres as per balance sheet) Basic and diluted earings per share (of Rs. 2 each)	20,755.05 16,485.96 3,362.91 915.19 2,151.54 639.34 1,927.72 805.85 500.00 500.00 8.61 2.56	74.457.95 7,266.35 5,444 07 5,384.02 500.00 29,580.50 21.78

Note:

1. The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results is available on the Stock Exchange websites (www.nseindia.com, www.bseindia.com) and Company's website (www.astrazeneca.com/india).

2. The financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to lhe extent applicable.

Place: Bengaluru Date: 07-08-2019

By Order of the Board of Directo� For AstraZeneca Pharma India Limited Gagandeep Singh Bedi Managing Director

==> picture [450 x 77] intentionally omitted <==

==> picture [451 x 445] intentionally omitted <==